BNP Paribas Financial Markets
SGMO

BNP Paribas Financial Markets’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

BNP Paribas Financial Markets’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66 Hold
266
– – ﹤0.01% 5704
2025
Q4 		$112 Sell
266
-180
-40% -$95 ﹤0.01% 5604
2025
Q3 		$300 Sell
446
-1,001
-69% -$540 ﹤0.01% 5353
2025
Q2 		$783 Buy
1,447
+6
+0.4% +$4 ﹤0.01% 5175
2025
Q1 		$945 Buy
1,441
+1,000
+227% +$1.06K ﹤0.01% 5080
2024
Q4 		$450 Sell
441
-2,665
-86% -$4.87K ﹤0.01% 5181
2024
Q3 		$2.69K Hold
3,106
– – ﹤0.01% 3876
2024
Q2 		$1.11K Sell
3,106
-69,054
-96% -$37.3K ﹤0.01% 3861
2024
Q1 		$48.4K Sell
72,160
-350,597
-83% -$254K ﹤0.01% 3572
2023
Q4 		$230K Buy
422,757
+249,617
+144% +$115K ﹤0.01% 3154
2023
Q3 		$104K Buy
173,140
+72,108
+71% +$77.2K ﹤0.01% 3319
2023
Q2 		$131K Sell
101,032
-157,636
-61% -$215K ﹤0.01% 3166
2023
Q1 		$455K Buy
258,668
+105,748
+69% +$302K ﹤0.01% 2788
2022
Q4 		$480K Sell
152,920
-43,411
-22% -$168K ﹤0.01% 2601
2022
Q3 		$962K Buy
196,331
+164,006
+507% +$842K ﹤0.01% 2512
2022
Q2 		$134K Sell
32,325
-4,646
-13% -$20.1K ﹤0.01% 3255
2022
Q1 		$215K Buy
36,971
+12,495
+51% +$74.3K ﹤0.01% 3103
2021
Q4 		$184K Buy
24,476
+3,116
+15% +$27.1K ﹤0.01% 3422
2021
Q3 		$192K Buy
21,360
+15,048
+238% +$149K ﹤0.01% 3053
2021
Q2 		$75.6K Sell
6,312
-23,108
-79% -$262K ﹤0.01% 3123
2021
Q1 		$369K Buy
29,420
+9,258
+46% +$125K ﹤0.01% 2746
2020
Q4 		$315K Sell
20,162
-6,859
-25% -$80.3K ﹤0.01% 2685
2020
Q3 		$255K Buy
27,021
+11,162
+70% +$121K ﹤0.01% 2623
2020
Q2 		$142K Sell
15,859
-43,905
-73% -$407K ﹤0.01% 2631
2020
Q1 		$381K Sell
59,764
-337,795
-85% -$2.51M ﹤0.01% 2500
2019
Q4 		$3.33M Buy
397,559
+378,522
+1,988% +$3.48M 0.01% 1409
2019
Q3 		$172K Buy
19,037
+6,661
+54% +$74.7K ﹤0.01% 2831
2019
Q2 		$133K Sell
12,376
-9,781
-44% -$104K ﹤0.01% 2860
2019
Q1 		$211K Buy
22,157
+21,074
+1,946% +$215K ﹤0.01% 2668
2018
Q4 		$12.4K Sell
1,083
-3,515
-76% -$43.7K ﹤0.01% 3272
2018
Q3 		$77.9K Sell
4,598
-4,464
-49% -$67.8K ﹤0.01% 2877
2018
Q2 		$129K Sell
9,062
-84,898
-90% -$1.41M ﹤0.01% 2661
2018
Q1 		$1.79M Buy
93,960
+76,905
+451% +$1.64M ﹤0.01% 1442
2017
Q4 		$280K Buy
17,055
+8,915
+110% +$133K ﹤0.01% 2784
2017
Q3 		$122K Buy
8,140
+304
+4% +$3.36K ﹤0.01% 2685
2017
Q2 		$69K Buy
7,836
+7,382
+1,626% +$47.4K ﹤0.01% 3016
2017
Q1 		$2.36K Sell
454
-759
-63% -$3.04K ﹤0.01% 3499
2016
Q4 		$3.7K Sell
1,213
-3,578
-75% -$13K ﹤0.01% 3801
2016
Q3 		$22.2K Buy
4,791
+2,064
+76% +$10.5K ﹤0.01% 2838
2016
Q2 		$15.8K Buy
+2,727
New +$17.4K ﹤0.01% 2692
2016
Q1 		– Sell
-14,480
Closed -$132K – 3021
2015
Q4 		$132K Buy
14,480
+220
+2% +$1.7K ﹤0.01% 2160
2015
Q3 		$80.4K Buy
14,260
+8,472
+146% +$69.9K ﹤0.01% 2523
2015
Q2 		$64.2K Buy
5,788
+4,179
+260% +$53.9K ﹤0.01% 2336
2015
Q1 		$25.2K Buy
+1,609
New +$24.9K ﹤0.01% 2261
2014
Q4 		– Sell
-4,051
Closed -$43.7K – 2988
2014
Q3 		$43.7K Buy
4,051
+3,781
+1,400% +$49.4K ﹤0.01% 2679
2014
Q2 		$4.12K Buy
+270
New +$3.88K ﹤0.01% 2691
2014
Q1 		– Sell
-790
Closed -$11K – 3754
2013
Q4 		$11K Sell
790
-15,528
-95% -$179K ﹤0.01% 2586
2013
Q3 		$171K Sell
16,318
-2,421
-13% -$24K ﹤0.01% 2302
2013
Q2 		$146K Buy
+18,739
New +$163K ﹤0.01% 2445

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BNP Paribas Financial Markets's SGMO Position: Q1 2026 in Review

BNP Paribas Financial Markets held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 266 shares worth $66. The position accounts for ﹤0.01% of the portfolio, ranked #5704.

BNP Paribas Financial Markets first reported a position in SGMO in Q2 2013 and has held it in 49 quarters since. The position peaked at $3.33M in Q4 2019. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • BNP Paribas Financial Markets held 266 shares of SANGAMO THERAPEUTICS INC worth $66 as of Q1 2026.
  • BNP Paribas Financial Markets left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5704 holding.
  • BNP Paribas Financial Markets first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 49 quarters since.
  • BNP Paribas Financial Markets's SANGAMO THERAPEUTICS INC position peaked at $3.33M in Q4 2019.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.